Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Combined locoregional-immunotherapy for liver cancer.

Greten TF, Mauda-Havakuk M, Heinrich B, Korangy F, Wood BJ.

J Hepatol. 2019 May;70(5):999-1007. doi: 10.1016/j.jhep.2019.01.027. Epub 2019 Feb 7. Review.

PMID:
30738077
2.

The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma.

Agdashian D, ElGindi M, Xie C, Sandhu M, Pratt D, Kleiner DE, Figg WD, Rytlewski JA, Sanders C, Yusko EC, Wood B, Venzon D, Brar G, Duffy AG, Greten TF, Korangy F.

Cancer Immunol Immunother. 2019 Apr;68(4):599-608. doi: 10.1007/s00262-019-02299-8. Epub 2019 Jan 28.

3.

Tremelimumab in Combination With Microwave Ablation in Patients With Refractory Biliary Tract Cancer.

Xie C, Duffy AG, Mabry-Hrones D, Wood B, Levy E, Krishnasamy V, Khan J, Wei JS, Agdashian D, Tyagi M, Gangalapudi V, Fioravanti S, Walker M, Anderson V, Venzon D, Figg WD, Sandhu M, Kleiner DE, Morelli MP, Floudas CS, Brar G, Steinberg SM, Korangy F, Greten TF.

Hepatology. 2019 May;69(5):2048-2060. doi: 10.1002/hep.30482. Epub 2019 Mar 10.

PMID:
30578687
4.

Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.

Yu SJ, Ma C, Heinrich B, Brown ZJ, Sandhu M, Zhang Q, Fu Q, Agdashian D, Rosato U, Korangy F, Greten TF.

J Hepatol. 2019 Mar;70(3):449-457. doi: 10.1016/j.jhep.2018.10.040. Epub 2018 Nov 9.

PMID:
30414862
5.

Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma.

Brown ZJ, Yu SJ, Heinrich B, Ma C, Fu Q, Sandhu M, Agdashian D, Zhang Q, Korangy F, Greten TF.

Cancer Immunol Immunother. 2018 Aug;67(8):1305-1315. doi: 10.1007/s00262-018-2190-4. Epub 2018 Jun 29.

6.

Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells.

Ma C, Han M, Heinrich B, Fu Q, Zhang Q, Sandhu M, Agdashian D, Terabe M, Berzofsky JA, Fako V, Ritz T, Longerich T, Theriot CM, McCulloch JA, Roy S, Yuan W, Thovarai V, Sen SK, Ruchirawat M, Korangy F, Wang XW, Trinchieri G, Greten TF.

Science. 2018 May 25;360(6391). pii: eaan5931. doi: 10.1126/science.aan5931.

7.

Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients.

Khanna S, Graef S, Mussai F, Thomas A, Wali N, Yenidunya BG, Yuan C, Morrow B, Zhang J, Korangy F, Greten TF, Steinberg SM, Stetler-Stevenson M, Middleton G, De Santo C, Hassan R.

Clin Cancer Res. 2018 Jun 15;24(12):2859-2872. doi: 10.1158/1078-0432.CCR-17-3757. Epub 2018 Mar 30.

8.

CDK20 inhibition and immune checkpoint blockade: bringing cancer biology and tumour immunology together to develop novel treatment options for HCC.

Greten TF, Korangy F.

Gut. 2018 May;67(5):783-784. doi: 10.1136/gutjnl-2017-315091. Epub 2017 Oct 24. No abstract available.

9.

Systematic evaluation of immune regulation and modulation.

Stroncek DF, Butterfield LH, Cannarile MA, Dhodapkar MV, Greten TF, Grivel JC, Kaufman DR, Kong HH, Korangy F, Lee PP, Marincola F, Rutella S, Siebert JC, Trinchieri G, Seliger B.

J Immunother Cancer. 2017 Mar 21;5:21. doi: 10.1186/s40425-017-0223-8. eCollection 2017. Review.

10.

Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.

Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, Pratt D, Davis JL, Hughes MS, Heller T, ElGindi M, Uppala A, Korangy F, Kleiner DE, Figg WD, Venzon D, Steinberg SM, Venkatesan AM, Krishnasamy V, Abi-Jaoudeh N, Levy E, Wood BJ, Greten TF.

J Hepatol. 2017 Mar;66(3):545-551. doi: 10.1016/j.jhep.2016.10.029. Epub 2016 Nov 2.

11.

Shall we blame CD4 T cells for everything?

Greten TF, Korangy F.

Gut. 2017 May;66(5):763-764. doi: 10.1136/gutjnl-2016-312900. Epub 2016 Nov 1. No abstract available.

12.

Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches.

Greten TF, Wang XW, Korangy F.

Gut. 2015 May;64(5):842-8. doi: 10.1136/gutjnl-2014-307990. Epub 2015 Feb 9. Review.

13.

Systemic Agonistic Anti-CD40 Treatment of Tumor-Bearing Mice Modulates Hepatic Myeloid-Suppressive Cells and Causes Immune-Mediated Liver Damage.

Medina-Echeverz J, Ma C, Duffy AG, Eggert T, Hawk N, Kleiner DE, Korangy F, Greten TF.

Cancer Immunol Res. 2015 May;3(5):557-66. doi: 10.1158/2326-6066.CIR-14-0182. Epub 2015 Jan 30.

14.

Tumor-induced CD11b(+) Gr-1(+) myeloid-derived suppressor cells exacerbate immune-mediated hepatitis in mice in a CD40-dependent manner.

Kapanadze T, Medina-Echeverz J, Gamrekelashvili J, Weiss JM, Wiltrout RH, Kapoor V, Hawk N, Terabe M, Berzofsky JA, Manns MP, Wang E, Marincola FM, Korangy F, Greten TF.

Eur J Immunol. 2015 Apr;45(4):1148-58. doi: 10.1002/eji.201445093. Epub 2015 Feb 23.

15.

Tumor induced hepatic myeloid derived suppressor cells can cause moderate liver damage.

Eggert T, Medina-Echeverz J, Kapanadze T, Kruhlak MJ, Korangy F, Greten TF.

PLoS One. 2014 Nov 17;9(11):e112717. doi: 10.1371/journal.pone.0112717. eCollection 2014.

16.

Immunogenicity of necrotic cell death.

Gamrekelashvili J, Greten TF, Korangy F.

Cell Mol Life Sci. 2015 Jan;72(2):273-83. doi: 10.1007/s00018-014-1741-x. Epub 2014 Oct 2. Review.

17.

Intrahepatic landscape of regulatory T-cell subsets in chronically HCV-infected patients with cirrhosis and HCC.

Wang XF, Korangy F.

Hepatology. 2014 Nov;60(5):1461-2. doi: 10.1002/hep.27271. Epub 2014 Sep 25. No abstract available.

PMID:
24954163
18.

IFN-γ regulates survival and function of tumor-induced CD11b+ Gr-1high myeloid derived suppressor cells by modulating the anti-apoptotic molecule Bcl2a1.

Medina-Echeverz J, Haile LA, Zhao F, Gamrekelashvili J, Ma C, Métais JY, Dunbar CE, Kapoor V, Manns MP, Korangy F, Greten TF.

Eur J Immunol. 2014 Aug;44(8):2457-67. doi: 10.1002/eji.201444497. Epub 2014 Jun 16.

19.

Peptidases released by necrotic cells control CD8+ T cell cross-priming.

Gamrekelashvili J, Kapanadze T, Han M, Wissing J, Ma C, Jaensch L, Manns MP, Armstrong T, Jaffee E, White AO, Citrin DE, Korangy F, Greten TF.

J Clin Invest. 2013 Nov;123(11):4755-68.

20.

Hepatocellular carcinoma from an immunologic perspective.

Greten TF, Duffy AG, Korangy F.

Clin Cancer Res. 2013 Dec 15;19(24):6678-85. doi: 10.1158/1078-0432.CCR-13-1721. Epub 2013 Sep 12.

21.

Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma.

Kapanadze T, Gamrekelashvili J, Ma C, Chan C, Zhao F, Hewitt S, Zender L, Kapoor V, Felsher DW, Manns MP, Korangy F, Greten TF.

J Hepatol. 2013 Nov;59(5):1007-13. doi: 10.1016/j.jhep.2013.06.010. Epub 2013 Jun 22.

22.

Human Th17 cells in patients with cancer: Friends or foe?

Greten TF, Zhao F, Gamrekelashvili J, Korangy F.

Oncoimmunology. 2012 Nov 1;1(8):1438-1439.

23.

Primary sterile necrotic cells fail to cross-prime CD8(+) T cells.

Gamrekelashvili J, Ormandy LA, Heimesaat MM, Kirschning CJ, Manns MP, Korangy F, Greten TF.

Oncoimmunology. 2012 Oct 1;1(7):1017-1026.

24.

Cellular immune suppressor mechanisms in patients with hepatocellular carcinoma.

Zhao F, Korangy F, Greten TF.

Dig Dis. 2012;30(5):477-82. doi: 10.1159/000341695. Epub 2012 Oct 24. Review.

25.

Anti-Gr-1 antibody depletion fails to eliminate hepatic myeloid-derived suppressor cells in tumor-bearing mice.

Ma C, Kapanadze T, Gamrekelashvili J, Manns MP, Korangy F, Greten TF.

J Leukoc Biol. 2012 Dec;92(6):1199-206. doi: 10.1189/jlb.0212059. Epub 2012 Oct 17.

26.

Immune suppression: the hallmark of myeloid derived suppressor cells.

Haile LA, Greten TF, Korangy F.

Immunol Invest. 2012;41(6-7):581-94. doi: 10.3109/08820139.2012.680635. Review.

27.

Human CCR4+ CCR6+ Th17 cells suppress autologous CD8+ T cell responses.

Zhao F, Hoechst B, Gamrekelashvili J, Ormandy LA, Voigtländer T, Wedemeyer H, Ylaya K, Wang XW, Hewitt SM, Manns MP, Korangy F, Greten TF.

J Immunol. 2012 Jun 15;188(12):6055-62. doi: 10.4049/jimmunol.1102918. Epub 2012 May 21.

28.

S100A9 a new marker for monocytic human myeloid-derived suppressor cells.

Zhao F, Hoechst B, Duffy A, Gamrekelashvili J, Fioravanti S, Manns MP, Greten TF, Korangy F.

Immunology. 2012 Jun;136(2):176-83. doi: 10.1111/j.1365-2567.2012.03566.x.

29.

Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells.

Hoechst B, Gamrekelashvili J, Manns MP, Greten TF, Korangy F.

Blood. 2011 Jun 16;117(24):6532-41. doi: 10.1182/blood-2010-11-317321. Epub 2011 Apr 14.

PMID:
21493801
30.

Myeloid derived suppressor cells in human diseases.

Greten TF, Manns MP, Korangy F.

Int Immunopharmacol. 2011 Jul;11(7):802-7. doi: 10.1016/j.intimp.2011.01.003. Epub 2011 Jan 13. Review.

31.

Differential suppression of tumor-specific CD8+ T cells by regulatory T cells.

James E, Yeh A, King C, Korangy F, Bailey I, Boulanger DS, Van den Eynde BJ, Murray N, Elliott TJ.

J Immunol. 2010 Nov 1;185(9):5048-55. doi: 10.4049/jimmunol.1000134. Epub 2010 Oct 4.

32.

Radiofrequency ablation for the treatment of HCC--maybe much more than simple tumor destruction?

Greten TF, Korangy F.

J Hepatol. 2010 Oct;53(4):775-6. doi: 10.1016/j.jhep.2010.05.008. Epub 2010 Jun 20. No abstract available.

33.

Immunotherapy of hepatocellular carcinoma.

Korangy F, Höchst B, Manns MP, Greten TF.

Expert Rev Gastroenterol Hepatol. 2010 Jun;4(3):345-53. doi: 10.1586/egh.10.18. Review.

PMID:
20528121
34.

CD49d is a new marker for distinct myeloid-derived suppressor cell subpopulations in mice.

Haile LA, Gamrekelashvili J, Manns MP, Korangy F, Greten TF.

J Immunol. 2010 Jul 1;185(1):203-10. doi: 10.4049/jimmunol.0903573. Epub 2010 Jun 4.

35.

Lipopolysaccharide-mediated mast cell activation induces IFN-gamma secretion by NK cells.

Vosskuhl K, Greten TF, Manns MP, Korangy F, Wedemeyer J.

J Immunol. 2010 Jul 1;185(1):119-25. doi: 10.4049/jimmunol.0902406. Epub 2010 May 28.

36.

A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma.

Greten TF, Forner A, Korangy F, N'Kontchou G, Barget N, Ayuso C, Ormandy LA, Manns MP, Beaugrand M, Bruix J.

BMC Cancer. 2010 May 17;10:209. doi: 10.1186/1471-2407-10-209.

37.

Immune responses in hepatocellular carcinoma.

Korangy F, Höchst B, Manns MP, Greten TF.

Dig Dis. 2010;28(1):150-4. doi: 10.1159/000282079. Epub 2010 May 7. Review.

PMID:
20460904
38.

Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC.

Greten TF, Ormandy LA, Fikuart A, Höchst B, Henschen S, Hörning M, Manns MP, Korangy F.

J Immunother. 2010 Feb-Mar;33(2):211-8. doi: 10.1097/CJI.0b013e3181bb499f.

PMID:
20139774
39.

Increase in frequency of myeloid-derived suppressor cells in mice with spontaneous pancreatic carcinoma.

Zhao F, Obermann S, von Wasielewski R, Haile L, Manns MP, Korangy F, Greten TF.

Immunology. 2009 Sep;128(1):141-9. doi: 10.1111/j.1365-2567.2009.03105.x.

40.

Identification of a novel murine pancreatic tumour antigen, which elicits antibody responses in patients with pancreatic carcinoma.

Zhao F, Vermeer B, Lehmann U, Kreipe H, Manns MP, Korangy F, Greten TF.

Immunology. 2009 Sep;128(1):134-40. doi: 10.1111/j.1365-2567.2009.03090.x.

41.

Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor.

Hoechst B, Voigtlaender T, Ormandy L, Gamrekelashvili J, Zhao F, Wedemeyer H, Lehner F, Manns MP, Greten TF, Korangy F.

Hepatology. 2009 Sep;50(3):799-807. doi: 10.1002/hep.23054.

42.

Molecular therapy for the treatment of hepatocellular carcinoma.

Greten TF, Korangy F, Manns MP, Malek NP.

Br J Cancer. 2009 Jan 13;100(1):19-23. doi: 10.1038/sj.bjc.6604784. Epub 2008 Nov 18. Review.

43.

Tumour-associated transcripts and EGFR deletion variants in colorectal cancer in primary tumour, metastases and circulating tumour cells.

Lankiewicz S, Rother E, Zimmermann S, Hollmann C, Korangy F, Greten TF.

Cell Oncol. 2008;30(6):463-71.

44.

Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway.

Haile LA, von Wasielewski R, Gamrekelashvili J, Krüger C, Bachmann O, Westendorf AM, Buer J, Liblau R, Manns MP, Korangy F, Greten TF.

Gastroenterology. 2008 Sep;135(3):871-81, 881.e1-5. doi: 10.1053/j.gastro.2008.06.032. Epub 2008 Jun 12.

PMID:
18674538
45.

A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells.

Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Krüger C, Manns MP, Greten TF, Korangy F.

Gastroenterology. 2008 Jul;135(1):234-43. doi: 10.1053/j.gastro.2008.03.020. Epub 2008 Mar 21. Erratum in: Gastroenterology. 2011 Aug;141(2):779.

PMID:
18485901
46.

Immunotherapy of HCC.

Greten TF, Manns MP, Korangy F.

Rev Recent Clin Trials. 2008 Jan;3(1):31-9. Review.

PMID:
18474013
47.

Participation in screening colonoscopy in first-degree relatives from patients with colorectal cancer.

Ruthotto F, Papendorf F, Wegener G, Unger G, Dlugosch B, Korangy F, Manns MP, Greten TF.

Ann Oncol. 2007 Sep;18(9):1518-22.

PMID:
17761708
48.

Peptide-beta2-microglobulin-major histocompatibility complex expressing cells are potent antigen-presenting cells that can generate specific T cells.

Obermann S, Petrykowska S, Manns MP, Korangy F, Greten TF.

Immunology. 2007 Sep;122(1):90-7. Epub 2007 Apr 30.

49.

Immune based therapies in cancer.

Krüger C, Greten TF, Korangy F.

Histol Histopathol. 2007 Jun;22(6):687-96. doi: 10.14670/HH-22.687. Review.

PMID:
17357098
50.

Necrotic tumor cell death in vivo impairs tumor-specific immune responses.

Gamrekelashvili J, Krüger C, von Wasielewski R, Hoffmann M, Huster KM, Busch DH, Manns MP, Korangy F, Greten TF.

J Immunol. 2007 Feb 1;178(3):1573-80.

Supplemental Content

Loading ...
Support Center